Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• 1,5 nmol/kg,GLP-1 sc injection (other) — also listed as: native GLP-1
• 1,5 nmol/kg GLP-1 9-36amide, sc injection (other)
• Exendin-4 ;10 ug,sc injection (other)
• saline (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Køge Hospital
  Køge, State..., Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• [68Ga]Ga-HBED-CC-PEG6-exendin-4 PET/CT (diagnostic_test) — also listed as: 68Ga-HBED-CC-PEG6-exendin-4
• [68Ga]Ga-HBED-CC-exendin-4 PET/CT (diagnostic_test) — also listed as: 68Ga-HBED-CC-exendin-4

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• 18F/68Ga-Exendin 4 (diagnostic_test)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• The First Affiliated Hospital of University of Science and Technology of China
  Hefei, Anhui, China
  Site recruitment: Recruiting
• The Affiliated Hospital of Qingdao University
  Qingdao, Shandong, China
  Site recruitment: Recruiting
• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• SGLT2 inhibitor (drug) — also listed as: CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
• DPP-4 inhibitor (drug) — also listed as: ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
• GLP-1RA (drug) — also listed as: INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE
• 2nd generation SU (drug) — also listed as: PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Brigham and Women's Hospital
  Boston, Massachusetts, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Glucagon-Like Peptide-1 Agonist (GLP-1) (drug) — also listed as: GLP-1RA

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• The Ohio State University
  Columbus, Ohio, United States
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• NLY01 (drug)
• Placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Johns Hopkins University
  Baltimore, Maryland, United States
  Site recruitment: Recruiting
• Mount Sinai School of Medicine
  New York, New York, United States
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• GLP-1 receptor agonist (drug) — also listed as: Bydureon BCise, Ozempic

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• First Affiliated Hospital of Wenzhou Medical University
  Wenzhou, Zhejiang, China
  Site recruitment: Recruiting
• Chinese University of Hong Kong
  Hong Kong, Hong Kong
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide (drug)
• Placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• CHU d'Angers
  Angers, France
  Site recruitment: Not reported
• CHU de Brest
  Brest, France
  Site recruitment: Not reported
• CHU de Grenoble
  Grenoble, France
  Site recruitment: Not reported
• CHU de Lyon
  Lyon, France
  Site recruitment: Not reported
• APHM
  Marseille, France
  Site recruitment: Not reported
• Hôpital Bicêtre
  Paris, France
  Site recruitment: Not reported
• Hôpital Cochin
  Paris, France
  Site recruitment: Not reported
• Hôpital Européen Georges Pompidou
  Paris, France
  Site recruitment: Not reported
• Hôpital Pitié Salpétrière (APHP)
  Paris, France
  Site recruitment: Not reported
• Hôpital Haut-Lévêque
  Pessac, France
  Site recruitment: Not reported
• CHU de Toulouse
  Toulouse, France
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• BYETTA treatment (drug)
• Metformine (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Assistance Publique Hopitaux de Marseille
  Marseille, France
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide extended release 2mg (Bydureon) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• University College London Hospital
  London, United Kingdom
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Magee Womens Hospital of UPMC
  Pittsburgh, Pennsylvania, United States
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Islets of Langerhans transplantation (biological) — also listed as: Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®), Exenatide (Byetta®)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• University of Illinois at Chicago Medical Center
  Chicago, Illinois, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• The First Affiliated Hospital of Henan University of Science and Technology
  Luoyang, Henan, China
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide 2 milligram (mg) Injection (drug) — also listed as: Bydureon
• Placebo (drug)
• Nicotine patch (drug)
• Smoking Cessation Counseling (behavioral)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Michael E. DeBakey VA Medical Center
  Houston, Texas, United States
  Site recruitment: Not reported
• The University of Texas Health Science Center at Houston
  Houston, Texas, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide (drug) — also listed as: Bydureon
• Placebo (drug) — also listed as: saline

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Michael E. DeBakey VA Medical Center
  Houston, Texas, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• BYDUREON (drug)
• Placebo (drug) — also listed as: Matching placebo subcutaneous injection

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Baylor Scott and White Research Institute- Baylor Heart and Vascular Hospital
  Dallas, Texas, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Experimental: GLP1-RA (exenatide) administration (drug) — also listed as: exenatide administration
• Control: Placebo administration (drug) — also listed as: placebo administration (sodium chloride)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Hospital de la Santa Creu i Sant Pau
  Barcelona, Spain
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Department of Endocrinology and Department of Nuclear Medicine, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072
  Chengdu, China
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Anti-Thymocyte Globulin (ATG) (drug) — also listed as: Thymoglobulin
• Interleukin 2 (drug) — also listed as: Aldesleukin; IL-2 or Proleukin®
• Exenatide (drug) — also listed as: Bydureon®
• Adalimumab (drug) — also listed as: HUMIRA®
• ATG Placebo (other)
• IL-2 Placebo (other)
• Adalimumab Placebo (other)
• Exenatide Placebo (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

The registry does not list facilities in this record. This does not mean the study has no sites.